Journal
ACTA PHARMACOLOGICA SINICA
Volume 41, Issue 9, Pages 1133-1140Publisher
NATURE PUBL GROUP
DOI: 10.1038/s41401-020-0438-y
Keywords
SARS-CoV-2; COVID-19; novel coronavirus pneumonia; therapeutic drugs; anti-SARS-CoV-2 agents; favipiravir; hydroxychloroquine; traditional Chinese medicine
Ask authors/readers for more resources
Since the outbreak of novel coronavirus pneumonia (COVID-19) in December 2019, more than 2,500,000 people worldwide have been diagnosed with SARS-CoV-2 as of April 22. In response to this epidemic, China has issued seven trial versions of diagnosis and treatment protocol for COVID-19. According to the information that we have collected so far, this article provides an overview of potential therapeutic drugs and compounds with much attention, including favipiravir and hydroxychloroquine, as well as traditional Chinese medicine, which have been reported with good clinical treatment effects. Moreover, with further understanding of SARS-CoV-2 virus, new drugs targeting specific SARS-CoV-2 viral components arise and investigations on these novel anti-SARS-CoV-2 agents are also reviewed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available